To extend these results obtained in primary AML blasts and to be able to perform more rigorous mechanistic analyses, we tested synergy between nutlin-3 and CPI203 in a panel of 3 human AML cell lines expressing wild-type p53 (OCI-AML3, MOLM13, MV411). The gene discussed is RUNX2; the disease is acute myeloid leukemia.